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A B S T R A C T
Objective: This prospective, population-based cohort study of 1102 Finnish adults with asthma, examined
whether exposure to stressful life events is associated with the intensity of usage of inhaled short-acting β2-
agonists.
Methods: Survey data was collected by two postal questionnaires. Baseline characteristics were obtained in 1998
and data on 19 specific stressful events (e.g. death of a child or spouse or divorce) within the six preceding
months in 2003. Exposure to life events was indicated by a sum score weighted by mean severity of the events.
Participants were linked to records of filled prescriptions for inhaled short-acting β2-agonists from national
registers from 2000 through 2006. The rates of purchases of short-acting β2-agonists before (2000−2001),
during (2002−2003) and after (2004–2006) the event exposure were estimated using repeated-measures
Poisson regression analyses with the generalized estimating equation.
Results: Of the 1102 participants, 162 (15%) were exposed to highly stressful events, 205 (19%) to less stressful
events. During the 7-year observation period, 5955 purchases of filled prescription for inhaled short-acting β2-
agonists were recorded. After exposure to highly stressful events, the rate of purchases of β2-agonists was 1.50
times higher (95% confidence interval (CI): 1.05, 2.13) than before the stressful event occurred. Among those
with low or no exposure to life events, the corresponding rate ratios were not elevated (rate ratio 0.81, 95% CI:
0.66, 0.99 and 0.95, 95% CI: 0.83, 1.09 respectively).
Conclusion: An increase in β2-agonist usage after severe life events suggests that stressful experiences may
worsen asthma symptoms.
1. Introduction
Asthma is a chronic intermittent inflammation of the large airways
[1,2] with the reported population prevalence varying from 2% in Es-
tonia to 21% in Australia [3]. Its prevalence is increasing in many
countries [4].A large number of studies on the biological risk factors for
asthma morbidity have found evidence of the etiological importance of
respiratory infections, allergens, air pollutants, and tobacco smoke
[5,6]. Recently, the role of psychosocial stress as a contributor of
asthma morbidity has gained increased attention [7,8]. Stress is
considered to affect the exacerbation of asthma through multiple im-
mune, endocrine, neural, and behavioural processes [9,10]. Stress also
accentuates the individual's immune response and induces changes in
inflammatory processes in the airways [11].
Some longitudinal cohort studies suggest an association between
negative stressful life events in the family and elsewhere and asthma
onset [12–14], while others have not found any association [15]. The
most recent study suggests that both work stress and family related life
events are positively associated with asthma in women [16]. In addi-
tion, life events may lead to a worsening of asthma among asthmatic
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adults [17–19]. Life events were risk factors for hospital admissions due
to asthma in a population based study [18] and hospital admission for
acute severe asthma in a case-control study [19]. Exposure to com-
munity violence was associated with both hospital admission and
emergency department visits due to asthma in a study among adults
[17] while long-lasting stress, at least at work, was not associated with
severe asthma exacerbations leading to hospitalization or death [20].
The previous studies scope on hospitalizations, which represent serious
exacerbations of asthma that occur at times in most patients and have
decreased during the last years [21].
Prescriptions of asthma medication may provide a way of assessing
day-to-day variation in everyday asthma symptoms in relation to in-
crease in life stress. To date, however, the association between recent
stressful life events and usage of inhaled bronchodilators has not been
studied in asthmatic adults in spite of the fact that a cornerstone of
successful treatment for asthma is self-management. It includes the
perception of asthma symptoms and the use of prescribed medication.
The aim of medication is to control the disease and to prevent its ex-
acerbation. Inhaled corticosteroids, in combination with or separate
from long-acting β2-agonists as anti-inflammatory drugs, play a major
role in this treatment. In addition, inhaled short-acting β2-agonists are
used for bronchodilation and protection against bronchoconstriction
and as quick-relief drugs for asthma symptoms. [22,23]
In this prospective study, we hypothesized that people with asthma
inhale short-acting β2-agonists when they are symptomatic and that
high exposure to recent stressful life events would be associated with
worsening symptoms, resulting in increased purchase of inhaled short-
acting β2−-agonist medication. To examine this, we used data of filled
prescriptions for asthmatic persons before, during, and after exposure
to recent stressful life events over a seven-year observation period. To
the best of our knowledge, no large-scale, general population studies
have examined changes in purchases of short-acting β2−-agonists fol-
lowing recent stressful life events among adults with diagnosed asthma.
2. Method
2.1. Study design and participants
The Health and Social Support Study, a longitudinal cohort study, is
based on a representative sample of the Finnish population in the age
groups: 20–24, 30–34, 40–44, and 50–54 years at baseline [24]. The
baseline postal survey was conducted in 1998, and a total of 25,901
respondents returned the questionnaire. Of them, 19,629 respondents
(80% of those eligible) participated in a follow-up survey 5 years later
in 2003 and 18,900 (96%) consented to the use of their recorded health
information from the Finnish national registers. For this study, we se-
lected all participants of the follow-up survey with asthma (n = 1102,
73% women) at the beginning of the 7-year observation window from
January 1, 2000 onward who had provided information on the occur-
rence of new life events within the preceding six months in the follow-
up survey. (Fig. 1) The study was approved by the Turku University
Hospital Ethics Committee. All participants signed an informed consent
form.
2.2. Participants with asthma
We used the unified personal identification code system, covering
all Finnish citizens, to link and obtain records from three administrative
and comprehensive Finnish national health registers to identify in-
dividuals with asthma and their purchases of prescribed asthma medi-
cations.
The identification of a participant having asthma at the beginning of
the follow-up was based on the clinical diagnosis of the treating phy-
sician in the records of the Drug Reimbursement Register of the Social
Insurance Institution (SII) of Finland [25] and/or the Hospital Dis-
charge Register of the National Institute for Health and Welfare. We
used the Drug Reimbursement Register of the SII of Finland containing
information on persons entitled to special reimbursement for certain
chronic diseases, such as asthma. Patients who apply for special re-
imbursement must attach a detailed medical certificate prepared by the
treating physician, who also provides data to confirm the diagnosis. The
application is then reviewed by a physician in the SII to determine
whether the uniformly defined requirements for the disease are met.
From this register, participants were defined as asthma cases if they
were for the first time recorded in the Central Drug Register as eligible
for asthma treatment before the start of the follow-up in January 1,
2000. Moreover, we used prescription data to assess the beginnings of
medical treatment for asthma. In Finland, the National Social Insurance
Scheme at the SII provides basic reimbursement for all filled outpatient
prescriptions that are recorded in the Drug Prescription Register ac-
cording to the World Health Organization's Anatomical Therapeutic
Chemical (ATC) Classification. The date of purchase is also recorded.
We identified all participants with two or more prescriptions for drugs
for obstructive airway diseases (ATC code R03) in 1998 and 1999 (the
two years preceding the beginning of the follow-up) by using the day of
the first purchase as an indicator of prevalent asthma. Finally, we ob-
tained data from the Hospital Discharge Register of the National In-
stitute for Health and Welfare, which includes records on all inpatient
hospital admissions [26]. This register is comprised of countrywide
information on virtually all hospitalizations. All participants discharged
from hospitals with the main diagnosis ICD-10 J45 (asthma) within the
two years preceding the beginning of the follow-up were also defined as
asthma cases.
2.3. Assessment of filled prescription for asthma medication during the 7-
year follow-up
In Finland, inhaled asthma medications are only available by pre-
scription. The National Health Insurance Scheme, run by the SII of
Finland, provides prescription drug coverage for all (~5.5 million)
community-dwelling residents of Finland. All reimbursed prescriptions
are registered in the Drug Prescription Register managed by the SII
[25]. For each drug, the dispensing date and the World Health Orga-
nization Anatomical Therapeutic Chemical (ATC) code are recorded.
We derived the date and the ATC classification code of purchases of
inhaled β2-agonists and corticosteroids during a seven-year observation
period covering the years 2000 to 2006 from the Drug Prescription
Register. For observation, we determined the number of purchases for
inhaled short-acting β2- agonists (ATC R03AC02, R03AC03 R03AC04)
and combinations of short-acting β2-agonists with anticholinergics
(ATC R03AK03, R03AK04).
Because the need for short-acting β2-agonists may depend on the
simultaneous usage of inhaled anti-inflammatory medication, we de-
termined the number of purchases for inhaled corticosteroids (ATC
R03BA01, R03BA02, R03BA05) and long-acting β2-agonists (ATC
R03AC12, R03AC13) in non-combination inhalers and fixed dose
combination inhalers of inhaled corticosteroids and long-acting β2-
agonists (ATC R03AK06, R03AK07). The number of purchases in every
year of observation was handled as a categorical factor in the model.
2.4. Recent stressful life events
We measured the occurrence of recent stressful life events in the
follow-up survey conducted in 2003 by using 19 life events from a list
of 21 events [27,28]. The excluded events (i.e., “illness causing work
disability of over 21 days” and “disability retirement”) might have been
a consequence of asthma exacerbation (see Appendix 1). For the timing
of each event, the questionnaire included four response alternatives
(never, within the previous 6 months, within the previous 5 yrs.
and> 5 yrs. ago), and the respondents were instructed to select only
one of them. The focus of this study is in recent events, those that had
occurred during the previous six months. We assessed the level of
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exposure to recent life events for each individual by calculating a cu-
mulative mean sum score weighted by the average severity of the event
(for weights, see Vahtera et al. [28]). The cumulative severity ratings
ranged from 2.74 to 24.64. Those respondents with a 0 (zero) score
were defined as having no exposure. Those who had been exposed were
divided into two groups using the median of the cumulative severity
score as the cut-off point (low exposure < 5, high exposure ≥ 5).
As shown in Appendix 1, only a small proportion of participants had
reported the corresponding event in the 1998 survey (e.g. 14% of those
who were victims of violence in 2003 reported to have been victims in
1998 also). Events with highest recurrence - breakup of long-term
friendship (43%), severe financial difficulties (40%) and death of a
close relative (35%) - were rated much less severe and, thus, had a
lower weight in the cumulative mean sum score.
2.5. Baseline characteristics
Baseline characteristics, measured in the baseline survey in 1998
before exposure to the life events included socio-demographic variables
– sex, age group, marital status, and level of education – behaviour-
related health risks, sensitivity to stress and depression. The behaviour-
related health risks were smoking (never/ex/current), high alcohol
intake (≥175 g of alcohol for women and ≥263 g of alcohol for men
per week) [29], obesity (Body Mass Index (BMI) ≥ 30 kg/m2) and
physical inactivity (the Metabolic Equivalent Task index< 2 MET-
hours/day) [30]. Individual differences in sensitivity to stress were
measured by general feelings of stressfulness in daily life [28,31]. The
mean scores of the scale were divided with tertiles, with the highest
third used as an indicator of sensitivity to stress. Depression, a potential
mediator between a stressful life event and asthma, was assessed using
the Beck Depression Inventory (sum score > 18) [32] and the Drug
Prescription Register [≥1 antidepressant (ATC-code N06A) purchases
in 1998]. Participants showing depression in any of these measure-
ments were classified as cases of pre-existing depression.
2.6. Statistical analysis
The association between background variables (demographics,
health-related factors, and psychological factors) (measured in 1998)
and recent stressful life-event exposure (measured in 2003) categories
were studied using the Pearson's chi-squared tests.
For the analyses, we divided the seven-year follow-up time into
three periods in relation to the timing of the life-event exposure: ‘be-
fore’ (i.e., year −3 and −2, 2000–2001), ‘during’ (i.e. year −1 and 0,
2002–2003) and ‘after’ (i.e. year +1 to +3, 2004–2006). We applied a
repeated-measures Poisson regression analysis with the generalized
estimating equation (GEE) method and autoregressive correlation
structure [33]. The GEE takes into account the correlation of annual
medication purchases within persons, and is not very sensitive to
missing cases at repeated measurements. We first examined the pur-
chases of inhaled short-acting bronchodilators by baseline character-
istic by calculating the mean rates of purchases over the seven-year
observation period for each characteristic.
We used contrasts to estimate the rate ratios and their 95% con-
fidence intervals (95% CI) during and after the exposure compared with
the period before the exposure - within each exposure group using
Fig. 1. Sample selection of subjects with asthma exposed to re-
cent stressful life events and linked to medication records
2000–2006, the Health and Social Support Study in Finland,
1998–2006. The identification of a respondents having asthma
was based on national registers.
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models including the interaction term “stressful life-event ex-
posure*period”. The rate ratios for purchases of inhaled short-acting β2-
agonists were calculated in the three time periods around the life-event
exposure. The analyses were adjusted for all baseline characteristics. An
additional adjustment was made for inhaled anti-inflammatory medi-
cation. In order to examine whether changes in purchases of inhaled
short-acting β2-agonists following exposure to life events varied be-
tween the subgroups (e.g. by sex, age group, education, behaviour-re-
lated health risks, depression or sensitivity to stress) we calculated the
rate ratios for each subgroup by using the same model. All tests were 2-
tailed.
All analyses were performed using the SAS Enterprise Guide 6.100
(6.100.0.2870) statistical software (SAS Institute Inc., Cary, NC, USA,
2013).
3. Results
3.1. Characteristics of the study population
The sample included 296 (27%) men and 806 (73%) women with
prevalent asthma at baseline. Of these individuals, 367 (33%) reported
an occurrence of new recent stressful life events in the follow-up survey.
The events reported most often were: ‘major increase in marital pro-
blems’ (n= 83), ‘severe financial difficulties’ (n = 77) or/and ‘death of
another close relative’ (n= 60). (Appendix 1). Table 1 shows the as-
sociations between the severity of life events exposed (no/low/high)
and the characteristics of participants; a young age, current or ex
smoking, and physical activity were associated with high life-event
exposure.
3.2. Purchases of inhaled short-acting β2-agonists
During the seven-year observation period, 5955 purchases of in-
haled short-acting β2-agonists were recorded for the participants. A
high annual purchase rate was observed among smokers, as well as
those with depression, obesity and those with a basic level of education
(Table 1).
3.3. Inhaled short-acting β2-agonists and recent stressful life events
Table 2 shows the rate ratios for purchases of inhaled short-acting
β2-agonists in the time periods during (year −1 and 0) and after (year
Table 1
Characteristics of the participant at baseline in 1998 by recent stressful life-event exposure levels in 2003 and annual mean rates for purchases of inhaled short-acting β2-agonists during
2000–2006, the health and social support study in Finland, 1998–2006.
Level of life-event exposure
All participants No Low High Purchases 2000–2006
No. % No. % No. % No. % P Valuea Mean rateb P Valuec
Total 1102 100 73 66 205 19 162 15
Sex 0.54 0.96
Men 296 27 200 27 58 28 38 23 77.6
Women 806 73 535 73 147 72 124 77 77.1
Age group < 0.001 0.20
20–24 242 22 135 18 57 28 50 31 64.1
30–34 239 22 145 20 53 26 41 25 79.2
40–44 252 23 171 23 48 23 33 20 71.5
50–54 369 33 284 39 47 23 38 24 88.5
Occupational education 0.070 0.035
University 177 16 129 18 29 14 19 12 59.7
College 335 31 211 29 74 37 50 31 69.4
Vocational school 237 22 158 22 34 17 45 28 75.0
Basic 336 31 225 31 64 32 47 29 94.5
Marital status 0.015 0.24
Single/divorced/widowed 326 30 199 27 65 32 62 38 85.4
Married/cohabiting 775 70 535 73 140 68 62 62 73.5
Smoking 0.003 < 0.001
Never-smoker 449 45 328 49 72 39 49 32 60.4
Ex-smoker 296 29 186 28 56 30 54 36 66.1
Current smoker 266 26 161 24 57 31 48 32 124.8
Physical inactivity 0.008 0.41
No 826 75 532 73 171 83 123 76 84.2
Yes 270 25 198 27 34 17 38 24 74.2
Obesity (BMI ≥ 30)d 0.53 0.007
No 921 84 609 83 173 84 139 87 68.8
Yes 175 16 122 17 32 16 21 13 124.0
High alcohol intakee 0.43 0.72
No 1046 95 701 96 193 94 152 94 77.0
Yes 53 5 31 4 12 6 10 6 84.1
Depression 0.36 0.036
No 981 89 659 90 183 89 139 86 73.5
Yes 121 11 76 10 22 11 23 14 107.4
Sensitivity to stress 0.066 0.22
No 720 66 496 68 127 62 97 60 72.4
Yes 374 34 232 32 77 38 65 40 86.3
Abbreviations: BMI, body mass index.
a P value for difference between the exposure groups (Pearson's chi-squared test).
b Annual average purchases of inhaled short-acting β2-agonists per 100 person years derived from Poisson regression generalized estimating equation (GEE) analysis for covariate.
c P value from Poisson regression GEE analysis for mean rates.
d BMI was calculated as weight (kg)/height (m2).
e High alcohol intake refers to consumption of> 175 g/week for women and> 263 g/week for men.
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+1 to +3), compared with the period before (year −3 and −2),
exposure to stressful life events adjusted for the baseline characteristics
(demographics, health risk behaviours, depression and sensitivity to
stress) and, additionally, for inhaled anti-inflammatory medication.
Among those with no exposure to recent stressful life events, the rate of
purchases did not significantly vary between the time periods. Among
participants who had encountered highly stressful recent life events, the
purchases of inhaled short-acting β2-agonists increased by 46% during
the life event exposure and 52% after the exposure compared with the
pre-exposure levels. This rate ratio remained unchanged after taking
into account adjustments for all baseline characteristics. Additionally,
adjustment for inhaled anti-inflammatory medication only slightly at-
tenuated the association (p < 0.06). Among participants who had low
exposure to recent stressful events, no increase between periods existed.
Results from the subgroup analyses are shown in Table 3. Compared
with the pre-exposure level, the rate of purchases of inhaled short-
acting β2-agonists increased in all subgroups of participants during and
after high life-event exposure. One exception was related to age; after
exposure, the youngest age group showed no increase in the rate of
purchases of inhaled short-acting β2-agonists. Interestingly, among
depressive participants (n = 121), the post-exposure increase was ex-
ceptionally high, 4.4-fold compared to the pre-exposure level.
Appendix 1 presents how many of the 367 participants reporting a
recent event at the follow-up survey in 2003 reported the corresponding
event also in the 1998 survey. As can be seen, for the most severe events
recurrence was non-existing or rare (e.g. only 14% of those who were
victims of violence in 2003 reported to have been victims in preceding
six months in 1998 also). Highest recurrence was found for ‘breakup of
long-term friendship’ (43%), ‘severe financial difficulties’ (40%) and
‘death of a close relative’ (35%), events rated much less severe.
4. Discussion
In this population-based 7-year follow-up study on adults with
asthma, records of filled prescriptions of inhaled short-acting β2-ago-
nists before, during and after exposure to stressful life-events were used
as an indicator of asthma symptoms. Among those who had en-
countered recent highly stressful life events, the rate for inhaled short-
acting β2-agonists purchases was 1.5 times higher after the life event
compared to the pre-event levels. No such increase was observed among
those with no or low exposure to stressful life events. These findings
support the hypothesis that psychosocial stress may exacerbate asthma
symptoms in working-aged adults.
Our results are consistent with the biopsychosocial model of stress,
which suggests that stressful life events may alter the psychological,
immunological and endocrine systems in ways that lead to the ex-
acerbation of asthma [9,34]. Moreover, the results of this study are in
line with the few studies which investigated the association between
stressful life events and the exacerbation of asthma symptoms in adults.
A case-control study by Kolbe et al. [19] found that life events were
reported more often among patients admitted to hospital with acute
asthma compared to a control group of non-hospitalized asthmatics. In
a prospective population based study by Wainwright et al. [18] life
events experienced in adulthood were associated with increased rates of
asthma-related hospital admissions. Although earlier studies provide
important insight on asthma exacerbation, hospital admissions for
asthma are considered very rare [21], representing only the tip of an
iceberg of asthma morbidity. In this study, the finding that the utili-
zation of inhaled short-acting β2-agonists varies depending on the ex-
tent to which asthmatic adults are exposed to life stress has not been
previously reported.
Stress may have an impact on individuals' life management and thus
affects asthma self-care and adherence to treatment [34], and increases
the risk of inappropriate use of asthma medications [35]. A recent study
found that many patients perceived stress was an important determi-
nant of uncontrolled asthma [36]. One indicator of such a development
is high use of short-acting bronchodilators with low use of inhaled
steroids [35]. As we were able to control in the analysis simultaneous
usage of anti-inflammatory medication, poor self-care of asthma is an
unlikely explanation for our time-dependent findings.
The strengths of this study are its large sample size and a study
design that allowed the determination of temporary order between
exposure to recent stressful life events and purchases of asthma medi-
cation. The number of filled prescriptions of inhaled short-acting β2-
agonists and the measurement of asthma were based on national health
registers. In Finland, the validity of the national registers has been
found to be high [37], reasonably accurate, and highly reliable for
epidemiological study purposes [38]. We were also able to control a
number of socio-demographic elements and etiological factors of
asthma.
A limitation of the study is that filled prescriptions do not equate to
actual medication utilization. Because we did not have information on
total amounts of drugs per prescription or recommended doses of the
asthma treatment, we were not able to use more fine-grained measures
such as increased daily doses of inhaled short-acting bronchodilators
use. However, short-acting beta-agonist prescription fills can be used as
a marker for asthma morbidity [39]. At baseline, the response rate was
relatively low (40%), and there may have been differences between
respondents and non-respondents regarding the frequency of asthma
and recent stressful life events, although no major health-related se-
lection has been detected in a non-response analysis [24]. How-
ever,> 80% of the baseline respondents participated in the follow-up
survey, and practically all of them (96%) consented to the linking of
data from national health registers. Thus, it is unlikely that the long-
itudinal association between recent stressful life events and asthma
exacerbation would be biased due to low participation at baseline.
Additionally, due to the applied survey methodology, we did not have
any additional information of the reported life events and their stress-
fulness. However, by using average severity rating instead of individual
perception of the severity of the event our measure was not confounded
by the consequences of the event for the individual.
Table 2
Rate Ratios for Purchases of Inhaled Short-Acting β2-Agonists Comparing Different Time
Periods According to Life-Event exposure, The Health and Social Support Study in
Finland, 1998–2006.
Adjustment level of stressful life-
event exposure
Time in relation to life-event exposure
Duringa vs beforec Afterb vs beforec
RRd 95% CI RRd 95% CI
Unadjusted
No exposure 0.98 0.88, 1.09 0.94 0.82, 1.07
Low exposure 0.84 0.75, 0.95 0.89 0.72, 1.10
High exposure 1.46 1.12, 1.90 1.52 1.06, 2.16
Baseline adjustede
No exposure 0.99 0.88, 1.11 0.95 0.83, 1.09
Low exposure 0.84 0.74, 0.96 0.81 0.66, 0.99
High exposure 1.47 1.12, 1.92 1.50 1.05, 2.13
Additionally adjustedf
No exposure 0.97 0.85, 1.10 0.92 0.79, 1.07
Low exposure 0.79 0.69, 0.91 0.74 0.62, 0.88
High exposure 1.43 1.09, 1.87 1.43 0.99, 2.07
Abbreviations: CI, confidence interval; RR, rate ratio.
a During refers to year −1 and 0 in relation to the timing of the life-event exposure.
b After refers to year +1 to +3 in relation to the timing of the life-event exposure.
c Before refers to year −3 and −2 in relation to the timing of the life-event exposure.
d Rate ratios (RR) and their 95% confidence limits (CI) derived from Poisson regression
generalized estimating equation analysis for time periods.
e Adjusted for sex, age, education, marital status, smoking, sedentary lifestyle, obesity,
high alcohol intake, depression and sensitivity to stress.
f Additionally adjusted for inhaled corticosteroids and long-acting β2-agonists in
combination or separate as time dependent variable.
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5. Conclusions
To the best of our knowledge, this is the first study to investigate the
longitudinal associations between recent stressful life events and pur-
chase levels in a population sample of adults with asthma at middle age.
Our finding that exposure to highly-stressful life events is associated
with an increase in inhaled short-acting β2-agonists purchases suggest a
worsening of asthma symptoms in the aftermath of stressful experi-
ences. These results highlight the potential importance of taking into
account psychosocial stress in guiding asthma self-care.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jpsychores.2017.07.003.
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University 0.97 0.69, 1.37 1.01 0.70, 1.47 0.80 0.64, 1.00 0.79 0.48, 1.32 1.21 0.55, 2.66 1.41 0.60, 3.34
College 0.91 0.74, 1.11 0.84 0.64, 1.11 0.90 0.68, 1.18 1.04 0.71, 1.52 1.57 0.96, 2.56 1.81 1.04, 3.14
Vocational school 0.98 0.79, 1.21 0.94 0.73, 1.21 0.83 0.65, 1.07 0.49 0.34, 0.72 1.13 0.75, 1.70 1.03 0.51, 2.06
Basic 1.04 0.87, 1.25 0.99 0.80, 1.22 0.85 0.71, 1.02 1.04 0.73, 1.46 1.89 1.28, 2.78 2.03 1.25, 3.30
Marital status
Single/divorced/widowed 0.96 0.79, 1.16 0.96 0.77, 1.21 0.91 0.75, 1.10 0.89 0.64, 1.26 1.31 0.95, 1.83 1.15 0.76, 1.74
Married/cohabiting 0.98 0.86, 1.12 0.92 0.78, 1.09 0.81 0.69, 0.94 0.87 0.67, 1.14 1.57 1.06, 2.31 1.80 1.09, 2.98
Smoking
Never-smoker 0.92 0.78, 1.07 0.88 0.74, 1.06 0.80 0.61, 1.05 0.89 0.60, 1.30 1.39 0.95, 2.02 1.40 0.97, 2.01
Ex-smoker 1.20 0.95, 1.51 1.16 0.91, 1.49 0.89 0.74, 1.08 0.77 0.55, 1.08 1.23 0.71, 2.16 1.34 0.60, 2.95
Current smoker 0.96 0.79, 1.16 0.96 0.75, 1.23 0.83 0.69, 1.01 0.80 0.57, 1.12 1.65 1.04, 2.62 1.62 0.84, 3.12
Physical inactivity
No 1.00 0.88, 1.15 0.95 0.81, 1.11 0.81 0.71, 0.93 0.92 0.73, 1.17 1.35 1.04, 1.75 1.28 0.86, 1.90
Yes 0.90 0.77, 1.07 0.90 0.72, 1.13 0.99 0.73, 1.34 0.77 0.51, 1.18 1.97 0.84, 4.61 2.64 1.17, 5.95
Obesity (BMI ≥ 30)e
No 0.98 0.86, 1.12 0.94 0.80, 1.09 0.85 0.74, 0.98 0.87 0.69, 1.10 1.39 1.02, 1.89 1.39 0.93, 2.09
Yes 0.96 0.81, 1.14 0.93 0.74, 1.18 0.76 0.62, 0.92 0.94 0.62, 1.41 1.82 1.28, 2.57 2.19 1.39, 3.47
High alcohol intakef
No 0.97 0.87, 1.08 0.92 0.80, 1.06 0.82 0.72, 0.93 0.87 0.69, 1.10 1.44 1.10, 1.89 1.47 1.02, 2.12
Yes 1.18 0.74, 1.90 1.46 0.83, 2.57 1.07 0.89, 1.29 1.06 0.73, 1.53 2.23 0.66, 7.53 3.76 0.76, 18.50
Depression
No 0.99 0.88, 1.12 0.96 0.83, 1.11 0.84 0.73, 0.96 0.93 0.73, 1.18 1.34 1.02, 1.75 1.30 0.90, 1.88
Yes 0.90 0.73, 1.12 0.84 0.64, 1.11 0.86 0.66, 1.13 0.70 0.46, 1.07 2.93 1.47, 5.85 4.36 1.75, 10.84
Sensitivity to stress
No 0.97 0.84, 1.11 0.93 0.80, 1.09 0.77 0.67, 0.90 0.83 0.64, 1.07 1.36 0.97, 1.92 1.29 0.84, 1.97
Yes 0.99 0.83, 1.18 0.92 0.73, 1.15 0.97 0.78, 1.19 0.98 0.67, 1.42 1.56 1,00, 2.41 1.77 0.97, 3.25
Abbreviations: BMI, body mass index; CI, confidence interval; RR, rate ratio.
a During refers to year −1 and 0 in relation to the timing of the life-event exposure.
b After refers to year +1 to +3 in relation to the timing of the life-event exposure.
c Before refers to year −3 and −2 in relation to the timing of the life-event exposure.
d Rate ratios (RR) and their 95% confidence limits (CI) derived from Poisson regression generalized estimating equation analysis for time periods.
e BMI was calculated as weight (kg)/height (m2).
f High alcohol intake refers to consumption of> 175 g/week for women and> 263 g/week for men.
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